Effect of Chronic PDE5-Inhibition on Endothelial Function in Diabetics

This study has been completed.

First Received: January 9, 2007 No Changes Posted

Sponsored by:	IRCCS San Raffaele
Information provided by:	IRCCS San Raffaele
ClinicalTrials.gov Identifier:	NCT00420901

Purpose

chronic PDE5-Inhibition improves endothelial function in diabetics

Condition	Intervention	Phase
Diabetes	Drug: sildenafil	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Effect of Chronic Administration of Sildenafil on Endothelial Function in Men With Diabetes

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Sildenafil Sildenafil citrate

Further study details as provided by IRCCS San Raffaele:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	30
Study Start Date:	January 1999
Estimated Study Completion Date:	February 2000

Detailed Description:

Evaluation of endothelial function at baseline and after chronic administration of sildenafil in male subjects with diabetes

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00420901

Locations

Sponsors and Collaborators

IRCCS San Raffaele

Investigators

Study Director:

giuseppe rosano, md

San Raffaele EUR

More Information

No publications provided

Study ID Numbers:	HSRRM1999/4
Study First Received:	January 9, 2007
Last Updated:	January 9, 2007
ClinicalTrials.gov Identifier:	NCT00420901 History of Changes
Health Authority:	Italy: Ethics Committee

Keywords provided by IRCCS San Raffaele:

function
inhibition

Study placed in the following topic categories:

Vasodilator Agents
Phosphodiesterase Inhibitors
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases

Sildenafil
Cardiovascular Agents
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:

Vasodilator Agents
Phosphodiesterase Inhibitors
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Diabetes Mellitus

Endocrine System Diseases
Enzyme Inhibitors
Sildenafil
Cardiovascular Agents
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 09, 2009